62473-95-4 Usage
Heterocyclic compound
Yes
It contains a benzene ring fused to an isothiazole ring, making it a heterocyclic compound.
Methoxy group (-OCH3)
Attached to the isothiazole ring.
Dioxide group (-O-O-)
Attached to the benzene ring.
Pharmaceutical and agrochemical applications
Building block
It is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals.
Antioxidant properties
Potential
The compound has been found to have potential antioxidant properties, which can be useful in the development of new drug compounds.
Antimicrobial properties
Potential
It has also been found to have potential antimicrobial properties, making it valuable for the development of new drug compounds.
Materials science applications
Research
The compound has been used in research for its potential applications in the field of materials science.
Chemical structure
The compound has a benzene ring fused to an isothiazole ring, with a methoxy group at the 6-position and a dioxide group at the 1,1-position.
Solubility
Not mentioned
The material provided does not mention the solubility of the compound.
Stability
Not mentioned
The material provided does not mention the stability of the compound.
Reactivity
Not mentioned
The material provided does not mention the reactivity of the compound.
Check Digit Verification of cas no
The CAS Registry Mumber 62473-95-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,4,7 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 62473-95:
(7*6)+(6*2)+(5*4)+(4*7)+(3*3)+(2*9)+(1*5)=134
134 % 10 = 4
So 62473-95-4 is a valid CAS Registry Number.
62473-95-4Relevant articles and documents
Preparation method and medical application of benzisothiazole and benzothiophene
-
Paragraph 0241; 0252; 0253; 0260; 0270; 0271, (2021/08/19)
The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and/or preventing chronic kidney diseases/chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.
